The emergence of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the medical community. This groundbreaking dual GIP and GLP-1 agonist medication appears to deliver impressive improvements in weight reduction compared to previous therapies. Initial patient data have indicated marked reductions in body fat percentage